1. Home
  2. ANNX vs JQC Comparison

ANNX vs JQC Comparison

Compare ANNX & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.64

Market Cap

918.2M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$5.04

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
JQC
Founded
2011
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
918.2M
753.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ANNX
JQC
Price
$5.64
$5.04
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
2.3M
714.6K
Earning Date
03-02-2026
01-01-0001
Dividend Yield
N/A
11.13%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$4.82
52 Week High
$7.18
$5.65

Technical Indicators

Market Signals
Indicator
ANNX
JQC
Relative Strength Index (RSI) 45.15 40.19
Support Level $6.10 $5.04
Resistance Level $6.59 $5.17
Average True Range (ATR) 0.43 0.04
MACD -0.14 -0.01
Stochastic Oscillator 10.57 3.57

Price Performance

Historical Comparison
ANNX
JQC

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

Share on Social Networks: